用于切除EGFR突变的II-IIIA阶段非小细胞肺癌的辅助性伊科替尼 (ICTAN,GASTO1002):随机比较研究
Ning Li1, Wei Ou1, Chao Cheng2
1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Signal transduction and targeted therapy
|August 27, 2025
概括
在切除EGFR突变的非小细胞肺癌 (NSCLC) 患者中,辅助性伊科替尼显著改善了无病生存率和整体生存率. 6个月和12个月的持续时间都显示出与可管理的安全性概况相比的好处.
科学领域:
- 癌症学
- 临床试验
- 药理学
背景情况:
- 切除EGFR突变非小细胞肺癌 (NSCLC) 的辅助治疗仍然是一个研究领域.
- 皮肤生长因子受体氨酸激酶抑制剂 (EGFR- TKIs) 在辅助剂的有效性和最佳持续时间以前是未知的.
研究的目的:
- 在完全切除,EGFR突变,II-IIIA期NSCLC的患者中评估辅助性icotinib的疗效和安全性.
- 确定这种患者群体的EGFR- TKI辅助治疗的理想治疗时间.
主要方法:
- 一项3期随机对照试验 (ICTAN试验NCT01996098) 涉及251名切除EGFR突变NSCLC的患者.
- 患者接受了辅助化疗,随后接受了12个月的icotinib,6个月的icotinib,或观察.
- 主要终点是无病生存期 (DFS).
主要成果:
- 与观察结果相比,辅助性伊科替尼在12个月和6个月内显著改善了DFS和整体存活率.
- 在12个月和6个月的治疗期间,没有观察到DFS或OS的显著差异.
- 3级或更高的不良事件很少,发生在8. 3% (12个月的伊科替尼),6. 0% (6个月的伊科替尼) 和2. 4% (观察) 的患者中.
结论:
- 不管是6个月还是12个月,辅助性化学疗法对切除EGFR突变的II-IIIA期NSCLC患者提供了显著的生存益处.
- 辅助性伊科替尼的安全性是可控的,支持其作为一种治疗选择的考虑.
- 6个月的辅助性治疗似乎与12个月的疗效相似.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
